The supporting documentation are available for free at the Health Economics website.* Editorial: Variability in healthcare treatment costs amongst nine EU countries – results from the Health Basket Project by Reinhard Busse, Jonas Schrey gg and Peter C. Smith* The hospital costs of care for stroke patients in nine European countries? David Epstein, Anne Mason and Andrea Manca* Health service costs in Europe:-: transitive use of sequence – specific costs and reimbursement of primary hip replacement in nine countries from Tom Stargardt* cross-country comparisons of costs purchasing purchasing power parities with standardized cost categories by Jonas Schrey gg, Oliver Tiemann, Tom Stargardt and Reinhard Busse..
Year on the 6th cancer researchers and study co-author Rowan T. Chlebowski Explains seemingly contradictory findings about estrogen and breast cancerRowan T. Chlebowski, a principal investigator at Los Angeles Biomedical Research Institute , provided his assessment of the apparent contradictions between Women `s presented an earlier Health Initiative study and a new abstract 4th June at the 2011 American Society of Clinical Oncology are. Continue reading
In recent yearsg in cancer prognostic studies foundmay be Selective reporting bias taint many published studies of so-called prognostic factors – biological or genetic markers that can predict how patients fare during and after treatment, according to a new study in which 20. July issue of the Journal of the National Cancer Institute.
Contacts: Item#: John P. Ioannidis, University of Ioannina,# Editorial: NCI Press Office, 301-496-6641,Quotes: Item#: Kyzas PA, Loizou KT, Ioannidis JPA, selective reporting biases in Cancer prognostic factor studies. J Natl Cancer Inst 2005; 97:1043-55.# Editorial: McShane LM, Altman DG, Sauerbrei W, identification of clinically useful Cancer Progostic factors: What are we missing? Continue reading
The company several batches several batches of polyclonal antibodies and prepared them for commercialization, including the optimization of large scale production, purification and stabilization.. The recan project the optimal use of existing techniques by focusing on a new area. Produces produces a new range of products that make significant improvements over existing options. Professor Horej? Comments that collaboration was important – the project partners have been contacted before recan started, but they were each able to contribute different skills. The IMG laboratory developed most the recombinant proteins and used them for immunization and the production of the hybridoma cell lines delivering the monoclonal antibody.
Thereby forming fusion of specific antibody-producing cells with cancer cells hybrid cell, they grow in tissue culture, and holding and purification of the of unique produced. In this project, a first test group was used to produce antibodies monoclonal antibodies, monoclonal antibodies, and other derived antibodies from polyclonal antibodies produce. We have a standard technology used, says Professor Vaclav Horej? of the Institute of Molecular Genetics in Prague . But what is so special about our project is the products. Particular, monoclonal antibodies of unique specificity, with great commercial potential and in some cases also useful for the diagnosis of . Continue reading